Secondary carcinoma affecting the skeleton is the most common cause of hypercalcaemia in hospitalized patients (Fisken et al., 1980) , and usually indicates a poor prognosis. Prompt effective treatment may decrease morbidity allowing hospitalised patients to return home, and in some instances, enable them to tolerate additional treatment more readily. Our understanding of the pathogenesis of hypercalcaemia in carcinoma is incomplete. It is usually but not invariably associated with widespread skeletal metastases. The increased bone resorption may be accompanied by increased activity of osteoclasts but a direct effect of the tumour cells themselves on bone is also a possible mechanism (Stewart et al., 1982) . Rarely, hypercalcaemia is associated with increased bone resorption, but without obvious skeletal deposits (Mundy et al., 1984) and is though to be mediated by humoral mechanisms not yet well characterised (Stewart et al., 1983; Strewler et al., 1983) .
Adequate extracellular volume repletion is an important aspect of the treatment of hypercalcaemia which decreases renal tubular reabsorption of calcium and increases glomerular filtration and thus the filtered load of calcium (Hosking et al., 1981) . Agents which inhibit specifically osteoclast activity have also been used, including calcitonin, corticosteroids and mithramycin. However, the response to calcitonin is commonly variable and incomplete (Wilkinson, 1984) steroids are not always effective (Percival et al., 1984; Mundy et al., 1983) and mithramycin has toxic effects on bone marrow and liver (Stewart, 1983) , particulary if used with other cytotoxic agents. More recently, the use of several diphosCorrespondence: J.A. Kanis Received 22 October 1984; and in revised form 21 January 1985. phonates, has given encouraging results in the treatment of hypercalcaemia (Jung et al., 1981; Chapuy et al., 1980; van Breukelen et al., 1979 (Paterson et al., 1983) , and we report here our findings in patients with hypercalcaemia due to solid tumours.
Patients and methods
Seventeen episodes of hypercalcaemia were studied in 15 patients (9 women and 6 men) with disseminated carcinoma before and after treatment with clodronate (Table I) . Two patients (nos. 3 and 7) received a second course of clodronate which was separated by a treatment free interval of 5-6 weeks.
Patients were admitted to the study if their values for serum calcium were above normal (2.1-2.6mmoll-1) and either stable or rising in a 48h control period despite adequate hydration. Six of the patients had received prednisolone (10-40mg daily), but had failed to show any hypocalcaemic response despite treatment for 12 to 28 days. Where hypocalcaemic agents (including i.v. fluids or corticosteroids) were being administered in the period before treatment, these were continued in the same dose during the early period of treatment. All patients had scintigraphic or radiographic evidence of widespread skeletal metastases and one third had biochemical evidence for hepatic dysfunction.
Informed consent was obtained from all patients or from a relative where the patient was unfit to give consent. The study had the prior approval of the local Ethical Committee. All patients were fully hydrated as judged by clinical criteria before the start of treatment with clodronate. Clodronate was given by mouth in a single daily dose of 0.8-3.2g 2h before breakfast. This range of dose was chosen because earlier studies had shown this to be effective in Paget's disease and hypercalcaemia due to myeloma (Douglas et al., 1980; Paterson et al., 1983) . Patients were treated for periods ranging from 3 days to 3 months (Table I) .
After an overnight fast, urine was collected during a 2 h period before breakfast. A venous blood sample was obtained during this period and the serum separated. Calcium, phosphate, creatinine and albumin were measured in serum by a Technicon SMAC Autoanalyser. Serum calcium was adjusted for variations in serum albumin by the addition or subtraction of 0.02 mmol 1-for each g 1 -that albumin was below or above 42 g/1.
Urinary calcium and hydroxyproline were expressed as ratios of urinary creatinine, which in the fasting state provided indices of net calcium release from bone and of bone resorption (Nordin, 1976; Cundy et al., 1983) .
The significance of changes in mean values was computed using Student's t-test for paired or nonpaired observations as appropriate. Results are shown as means (±s.e.).
Results
The administration of clodronate resulted in a progressive fall in serum calcium in 14 of the 17 episodes studied. The maximum effect on serum calcium was seen one week after starting treatment. Mean serum calcium fell from 3.23+0.08mmoll-' to 2.85+0.09mmoll-1 at 1 week (Figure 1) , and normal values for serum calcium were observed in 9 patients. In 14 studies (on 13 patients) treatment was continued for 3 to 10 weeks. In all but 4 patients a hypocalcaemic response was sustained for the duration of treatment though mean values rose slightly (Figure 1) Three patients failed to show a substantial fall in serum calcium. In two however, a marked fall in urinary calcium/creatinine was noted (eg Figure 2) suggesting that the reduction in bone resorption had been masked by a simultaneous rise in renal tubular reabsorption for calcium. patients with solid tumours. However, the magnitude of the hypocalcaemic response was less than in our own series of patients with hypercalcaemia due to myeloma treated identically with clodronate (Paterson et al., 1983) . Unfortunately, assays for the diphosphonates are not widely available nor easy to interpret (Kanis, 1985) , so that it was not possible to document the bioavailibility of the drug. Despite this difficulty it is likely that clodronate decreased bone resorption to a similar extent in both myeloma and our patients with solid tumours. Thus net calcium release from bone, as judged by the calcium/creatinine ratio, was suppressed to a similar extent in myeloma and carcinoma, which suggests that the less complete response in patients with carcinoma was due to other mechanisms. Indeed, in 2 patients in whom plasma calcium did not change, there was evidence for effective suppression of excessive bone resorption. The lack of fall in serum calcium was probably due to to an increase in renal tubular reabsorption of calcium, and others have suggested that increased renal tubular E U resorption of calcium is an important component of malignant hypercalcaemia.
It is unlikely that the hypocalcaemic responses were due to changes in the state of hydration, as serum creatinine, albumin and haemocrit did not change during treatment.
The changes in fasting calcium excretion were more marked than changes in urinary hydroxyproline excretion. This finding is similar to the experience of others in solid tumours (Chapuy et al., 1980) and to our findings in myeloma (Paterson et al., 1983) . It is probable that hydroxyprolinuria is partly due to collagen turnover of tumour tissue and that this masked the effects of diphosphonate treatment on bone-derived collagen.
There are now a number of reports that several different diphosphonates provide a simple and effective treatment for hypercalcaemia due to increased bone resorption (Chapuy et al., 1980; van Breukelen et al., 1979; Jacobs et al., 1981; Douglas et al., 1980; Mundy et al., 1983; Jung et al., 1981) . The only commercially available diphosphonate (etidronate) is a powerful inhibitor of bone resorption but also impairs mineralisation of bone, particularly when high doses are used (Boyce et al., 1984) . This unwanted effect decreases calcium entry into bone and may explain the less complete hypocalcaemic effect of this agent .
The newer diphosphonates (clodronate and aminopropylidene diphosphonate) which are currently undergoing clinical evaluation, appear to have less effect on the mineralisation process. There have been concerns that clodronate might be leukaemogenic based on the finding of acute myeloid leukaemia in 3 patients given clodronate. Investigation of these patients and surveillance of patients given clodronate is continuing to assess the significance of these observations. Our own view is that this was a coincidental rather than causal relationship.
Our own studies with clodronate indicate that, despite its poor absorption from the gastrointestinal tract (Yakatan et al., 1982) , oral administration is an effective method of controlling bone resorption which can be inhibited for as long as treatment is continued. Moreover the long-term administration of clodronate to patients with breast cancer may delay the appearance of osteolysis (Elomaa et al., 1983; Jung et al., 1983) . These observations suggest that the use of diphoshonates may modify the natural history of skeletal metastases in patients with solid tumours. Whether or not this might improve survival is far from clear, but is likely to decrease considerably the morbidity associated with hypercalcaemia and7fracture.
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